Layered immunity and layered leukemogenicity: Developmentally restricted mechanisms of pediatric leukemia initiation.
Jonny Mendoza-CastrejonJeffrey A MageePublished in: Immunological reviews (2023)
Hematopoietic stem cells (HSCs) and multipotent progenitor cells (MPPs) arise in successive waves during ontogeny, and their properties change significantly throughout life. Ontological changes in HSCs/MPPs underlie corresponding changes in mechanisms of pediatric leukemia initiation. As HSCs and MPPs progress from fetal to neonatal, juvenile and adult stages of life, they undergo transcriptional and epigenetic reprogramming that modifies immune output to meet age-specific pathogenic challenges. Some immune cells arise exclusively from fetal HSCs/MPPs. We propose that this layered immunity instructs cell fates that underlie a parallel layered leukemogenicity. Indeed, some pediatric leukemias, such as juvenile myelomonocytic leukemia, myeloid leukemia of Down syndrome, and infant pre-B-cell acute lymphoblastic leukemia, are age-restricted. They only present during infancy or early childhood. These leukemias likely arise from fetal progenitors that lose competence for transformation as they age. Other childhood leukemias, such as non-infant pre-B-cell acute lymphoblastic leukemia and acute myeloid leukemia, have mutation profiles that are common in childhood but rare in morphologically similar adult leukemias. These differences could reflect temporal changes in mechanisms of mutagenesis or changes in how progenitors respond to a given mutation at different ages. Interactions between leukemogenic mutations and normal developmental switches offer potential targets for therapy.
Keyphrases
- acute myeloid leukemia
- acute lymphoblastic leukemia
- allogeneic hematopoietic stem cell transplantation
- bone marrow
- childhood cancer
- stem cells
- reduced graphene oxide
- highly efficient
- gene expression
- single cell
- transition metal
- dna methylation
- young adults
- transcription factor
- ion batteries
- mesenchymal stem cells
- crispr cas
- body mass index
- early life
- gold nanoparticles